Weekly News Wrap-up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news

1. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page1
Focus on Europe
Focus on North America
Focus on Asia Pacific
AstraZeneca has sold the European marketing rights for the opioid-induced constipation drug
Moventig to ProStrakan, a unit of Japanese biopharma firm Kyowa Hakko Kirin. (Fortune)
Eurofins Scientific announced its entry into the biopharmaceutical products testing market in the
Asia Pacific region with the acquisition of ams Laboratories Pty Ltd. (RTTNews)
Genmab announced that it has reached a $5 million milestone in the Phase 2 study of Darzalex
(daratumumab) as a potential treatment for non-Hodgki ’s ly pho a (NHL). (lymphomanewstoday)
GlaxoSmithKline is cutting ties with Five Prime Therapeutics' in-development cancer therapy,
backing out in the middle of a mesothelioma trial. (fiercebiotech)
Novo Nordisk announced that the results from a trial showed that its Victoza diabetes drug
significantly reduced the risks of major adverse cardiovascular events. (Reuters)
Sanofi is accelerating the development of a Zika vaccine, having assembled a team of more than 80
in-house experts who would start preclinical tests of a potential vaccine this spring. (Fortune)
Weekly News Wrap-Up: HEALTH CARE Industry
No. 2
2016-03-13
AbbVie Allergan Amgen Astellas AstraZeneca Eurofins Scientific Genmab
GlaxoSmithKline Medtronic Novo Nordisk Pfizer Primary Health Care Sanofi
SPOTLIGHT
COMPANY NEWS
AbbVie Inc s Humira, the best-selling drug in the world in 2014, with total sales of $12.5 billion,
reached just over $14 billion in 2015. (investorplace)
Allergan plc announced the receipt of a Complete Response Letter from the FDA for its Prior
Approval Supplement (PAS) for RESTASIS®. (streetinsider)
Amgen announced that the FDA has accepted for review its supplemental Biologics License
Application (sBLA) for the expanded use of Enbrel® (etanercept). (streetinsider)
Medtronic announced European enrollment in the NAVIGATE clinical trial, a 2,500-patient
international lung cancer study. (fiercemedicaldevices)
Pfizer Inc‘s application for an Indian patent on a highly effective pneumonia vaccine has been
formally opposed by Medicins Sans Frontieres. (Reuters)
Astellas published the results from the Phase 3 VITAL trial evaluating CRESEMBA® (isavuconazonium
sulfate) in adult patients with invasive mucormycosis. (Satellite PR News)
Primary Health Care’s i teri report sho s a age e t’s hope for a stro ger seco d half ith
projects underway to drive margin expansion and recycle capital. (TheMotleyFool)
Sonic Healthcare Limited, Australia’s largest pathology a d diag ostic i agi g pro ider, reports solid
interim results with strong earnings growth. (TheMotleyFool)

2. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page2
98%
100%
102%
2016-03-07 2016-03-08 2016-03-09 2016-03-10 2016-03-11
Europe North America Asia/Pacific
Regional Comparison
Focus on Europe
Ha i g a look at a regio al split up of the orld’s iggest listed health care co pa ies, it eco es
clear that the European and North American market showed similar development of rounded +0.3%
while the Asian/Pacific region suffered from a decline of -1.8% this week. On a yearly basis however,
Europe decreased by -13.7%, North America by -11.9% whereas Asia/Pacific scored +1.0%.
Weekly News Wrap-Up: HEALTH CARE Industry
No. 2
2016-03-13
BB Biotech Essilor International Fresenius Hikma Pharmaceuticals Merck
Morphosys Novozymes Sanofi UCB William Demant
SPOTLIGHT
FINANCIAL MARKET NEWS
Index closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
STOXX® Europe 600
Health Care
710.42 +0.26% -13.72% 726.23 701.72 879.13 654.95
STOXX® North America 600
Health Care
807.12 +0.33% -11.88% 813.67 782.86 966.34 730.68
STOXX® Asia/Pacific 600
Health Care
421.89 -1.81% +0.99% 432.26 415.81 446.92 349.32
STOXX® Global 1800
Health Care
708.86 +0.11% -11.45% 718.22 692.16 842.76 647.94
This eek’s top performer from Europe is William Demant with an increase of +4.9% while its one
year performance reaches +13.3%. Second is BB Biotech with a value gain of +3.2% on a weekly basis
though it shows a negative development of -26.3% on a yearly basis.
top 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
William Demant 84.25 +4.95% +13.33% 84.25 80.51 91.73 66.45
BB Biotech 248.50 +3.24% -26.32% 232.19 220.60 338.63 177.51
Fresenius 62.15 +2.98% +17.30% 63.45 58.65 69.98 51.02
Essilor International 111.90 +2.19% +5.65% 116.43 109.23 127.50 95.87
Sanofi 73.96 +2.11% -16.93% 75.50 71.12 101.00 66.50
flop 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
Merck 76.16 -4.64% -24.45% 80.30 76.06 112.44 70.71
Hikma Pharmaceuticals 1,720.00 -4.01% -23.31% 1,793.00 1,704.00 2,520.00 1,596.82
Morphosys 39.87 -3.57% -45.13% 42.20 38.72 76.96 33.82
Novozymes 38.72 -2.69% -9.13% 40.05 38.72 48.60 33.91
UCB 67.75 -2.51% +5.77% 70.36 67.80 85.56 60.84
On the other side, the lowest performer from Europe this week is Merck with a decrease of -4.6%,
thereby exacerbating its one year loss of -24.4%. Second worst performing stock from Europe is
Hikma Pharmaceuticals which dropped by -4.0%, reaching a decline of -23.3% on a yearly basis.